Johnson & Johnson (JNJ) — ESG & Values Scores

Environment story

J&J discloses a 26% absolute reduction in Scope 1 & 2 GHG emissions from 2021-2024, indicating some operational decarbonization progress, but the filings reviewed do not disclose Scope 3 emissions trends or a specific net-zero target year, both of which are treated as gaps under a conservative scoring framework. No specific toxic-waste or localized water-consumption controversy is documented in the reviewed filings, though generic climate-related physical and regulatory risks (water scarcity, extreme weather) are acknowledged as risk factors.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Scope 1 & 2 GHG Reduction

26% reduction in absolute Scope 1 & 2 GHG emissions achieved between 2021-2024, as reported in the 2026 Proxy Statement's 'Living into Our Credo' section.

Operational emissions reduction; mechanism (efficiency vs. offsets) not detailed in source text.
Sustainability Governance Oversight

Regulatory Compliance & Sustainability Committee of the Board reviews sustainability strategy at least semi-annually with updates from the Chief Sustainability Officer.

Board-level oversight structure for environmental strategy.

Social story

The reviewed 10-K and proxy do not disclose a specific CEO-to-median-worker pay ratio figure, leadership diversity percentages, or documented union-suppression activity/strikes within the last 24 months, so no rubric deductions were triggered based on available data. The Company faces significant, long-running product liability litigation (notably talc-related lawsuits tied to JOHNSON'S Baby Powder) that has material financial and reputational implications, though this is categorized primarily as a product-safety/litigation matter rather than a labor or diversity metric under this rubric.

Criticisms on file

Ongoing product liability litigation alleging health harms from talc-containing body powders (primarily JOHNSON'S Baby Powder), involving thousands of plaintiffs and a reserve balance of approximately $3.4 billion for talc matters as of year-end 2025.
Source: JNJ_10k.txt (Risk Factors; MD&A Liquidity and Capital Resources section)
Approximately $1.1 billion remaining reserve to settle opioid litigation as of year-end 2025.
Source: JNJ_10k.txt (MD&A Liquidity and Capital Resources section)

Disclosed initiatives

Employee Wellbeing Programs

89% of responding employees rated comprehensive health and wellbeing offerings favorably (highest rating to date, per 2026 Proxy).

Reported employee satisfaction metric.
Learning & Development

85% of responding employees reported meaningful skill-building opportunities; ~500,000 learning hours logged during a Global Learning Day.

Workforce development investment.
Community Health Programs

200,000 community health workers deployed via The Johnson & Johnson Foundation for Africa Frontline First; 1.4 million nurses/healthcare workers equipped with skills training.

Global public health capacity building.

Governance story

J&J maintains a single class of common stock (no dual-class structure) and board independence of 11 of 12 nominees (~91.7%), exceeding the 75% threshold. However, the Company discloses several significant, active legal and regulatory proceedings, including multi-billion-dollar talc litigation, opioid litigation, Auris shareholder litigation ($0.8 billion expense in 2025), and constitutional litigation against the U.S. government challenging IRA drug-pricing provisions, which collectively represent material governance and regulatory risk.

Criticisms on file

Shareholder proposal for an independent Board Chair (2026 proxy Item 4) opposed by the Board; a similar 2021 proposal received ~43% support, indicating notable shareholder governance concerns regarding CEO/Chair combination.
Source: JNJ_proxy.txt (Item 4: Shareholder proposal — independent board chair)
Auris Health shareholder litigation resulting in $0.8 billion expense recorded in 2025.
Source: JNJ_10k.txt (MD&A Other Income/Expense section)
Janssen (J&J subsidiary) litigation against HHS/CMS challenging constitutionality of the IRA's Medicare Drug Price Negotiation Program, with Supreme Court review sought in December 2025.
Source: JNJ_10k.txt (MD&A Economic and Market Factors section)

Disclosed initiatives

Board Refreshment

Two new independent directors added in 2025 (Daniel Pinto, John Morikis); average director tenure ~5.5 years.

Ongoing board composition renewal.
Political Spending Disclosure

Early mover on disclosure of corporate political expenditures and activities; PAC and U.S. corporate political spending audited biennially by internal auditors.

Enhanced transparency on political engagement.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Johnson & Johnson. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Johnson & Johnson in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO) Abbott Laboratories (ABT)